GT201200284A - Composición farmacéutica - Google Patents
Composición farmacéuticaInfo
- Publication number
- GT201200284A GT201200284A GT201200284A GT201200284A GT201200284A GT 201200284 A GT201200284 A GT 201200284A GT 201200284 A GT201200284 A GT 201200284A GT 201200284 A GT201200284 A GT 201200284A GT 201200284 A GT201200284 A GT 201200284A
- Authority
- GT
- Guatemala
- Prior art keywords
- pharmaceutical composition
- efavirenz
- understands
- nanoparticles
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1296MU2010 | 2010-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201200284A true GT201200284A (es) | 2014-08-26 |
Family
ID=44625957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201200284A GT201200284A (es) | 2010-04-20 | 2012-10-18 | Composición farmacéutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130302415A1 (enExample) |
| EP (1) | EP2560617A2 (enExample) |
| JP (1) | JP2013525337A (enExample) |
| KR (1) | KR20130076818A (enExample) |
| CN (1) | CN102985072A (enExample) |
| AU (1) | AU2011244783B2 (enExample) |
| BR (1) | BR112012026843A2 (enExample) |
| CA (1) | CA2796494A1 (enExample) |
| GT (1) | GT201200284A (enExample) |
| NZ (1) | NZ602955A (enExample) |
| RU (1) | RU2012149115A (enExample) |
| WO (1) | WO2011131943A2 (enExample) |
| ZA (1) | ZA201207670B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115633D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of efavirenz |
| US10646452B2 (en) * | 2013-03-15 | 2020-05-12 | New Jersey Institute Of Technology | System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process |
| WO2015059466A1 (en) | 2013-10-25 | 2015-04-30 | Cipla Limited | Pharmaceutical compositions comprising efavirenz |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| IN2014MU00916A (enExample) * | 2014-03-20 | 2015-09-25 | Cipla Ltd | |
| CN104224790A (zh) * | 2014-09-28 | 2014-12-24 | 苏州普罗达生物科技有限公司 | 一种依法韦仑组合物及其制备方法 |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| AU2017364077A1 (en) | 2016-11-22 | 2019-06-20 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| AU2018306303A1 (en) * | 2017-07-25 | 2020-02-20 | Elektrofi, Inc. | Formation of particles including agents |
| US20230040901A1 (en) * | 2018-01-04 | 2023-02-09 | PlantTec Medical GmbH | Pharmaceutical composition for inhibiting postoperative adhesions |
| ES2732498B2 (es) * | 2018-05-21 | 2020-04-27 | Consejo Superior Investigacion | Uso de efavirenz para el tratamiento de enfermedades de almacenamiento lipidico. |
| US12115262B2 (en) | 2018-05-24 | 2024-10-15 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| CN112236141A (zh) * | 2018-06-11 | 2021-01-15 | 大塚制药株式会社 | 包含德拉马尼的组合物 |
| AU2020214626B2 (en) | 2019-01-31 | 2025-10-16 | Elektrofi, Inc. | Particle formation and morphology |
| JP7781743B2 (ja) | 2019-09-13 | 2025-12-08 | エレクトロフィ,インコーポレイテッド | 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法 |
| WO2021110697A1 (en) * | 2019-12-02 | 2021-06-10 | Astrazeneca Ab | Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine |
| JP2023522627A (ja) | 2020-04-17 | 2023-05-31 | エレクトロフィ,インコーポレイテッド | 連続的な液滴形成及び脱水によって粒子を形成する方法 |
| WO2021216475A1 (en) * | 2020-04-20 | 2021-10-28 | Poviva Corp. | Compositions and methods for enhanced delivery of antiviral agents |
| CN112245400B (zh) * | 2020-11-10 | 2023-01-20 | 蓝龙药业(北京)有限公司 | 一种依法韦仑微片剂、制备方法及其应用 |
| CN114404377B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72207C2 (uk) | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| EP1332757B1 (en) * | 1998-05-27 | 2012-06-13 | Merck Sharp & Dohme Corp. | Efavirenz compressed tablet formulation |
| CO5070643A1 (es) | 1998-05-27 | 2001-08-28 | Merck & Co Inc | Formulacion en tabletas comprimidas |
| WO2003045327A2 (en) * | 2001-11-27 | 2003-06-05 | Bristol-Myers Squibb Company | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| WO2007002823A2 (en) * | 2005-06-29 | 2007-01-04 | Wyeth | Formulations of conjugated estrogens and bazedoxifene |
| US20080026062A1 (en) * | 2006-07-31 | 2008-01-31 | Isaac Farr | Pharmaceutical compositions including nano-sized active agent |
| TWI405590B (zh) * | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | 微粉碎化有機化合物粒子之製法 |
| EP2076248A2 (en) * | 2007-08-17 | 2009-07-08 | Teva Pharmaceutical Industries Ltd. | Methods and compositions for controlling the bioavailability of poorly soluble drugs |
| JP4606444B2 (ja) * | 2007-08-21 | 2011-01-05 | アピ株式会社 | アントシアニン含有経口投与用組成物及びその製造方法 |
| US8846096B2 (en) * | 2008-12-12 | 2014-09-30 | Creighton University | Nanoparticles and methods of use |
| US10952965B2 (en) * | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| GB201006038D0 (en) * | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
-
2011
- 2011-04-20 AU AU2011244783A patent/AU2011244783B2/en not_active Ceased
- 2011-04-20 JP JP2013505533A patent/JP2013525337A/ja active Pending
- 2011-04-20 KR KR1020127030186A patent/KR20130076818A/ko not_active Ceased
- 2011-04-20 EP EP11716002A patent/EP2560617A2/en not_active Withdrawn
- 2011-04-20 RU RU2012149115/15A patent/RU2012149115A/ru not_active Application Discontinuation
- 2011-04-20 NZ NZ602955A patent/NZ602955A/en not_active IP Right Cessation
- 2011-04-20 WO PCT/GB2011/000620 patent/WO2011131943A2/en not_active Ceased
- 2011-04-20 CN CN2011800201397A patent/CN102985072A/zh active Pending
- 2011-04-20 CA CA2796494A patent/CA2796494A1/en not_active Abandoned
- 2011-04-20 BR BR112012026843A patent/BR112012026843A2/pt not_active IP Right Cessation
-
2012
- 2012-10-12 ZA ZA2012/07670A patent/ZA201207670B/en unknown
- 2012-10-18 GT GT201200284A patent/GT201200284A/es unknown
-
2013
- 2013-07-14 US US13/941,525 patent/US20130302415A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011131943A2 (en) | 2011-10-27 |
| WO2011131943A8 (en) | 2012-11-29 |
| CN102985072A (zh) | 2013-03-20 |
| EP2560617A2 (en) | 2013-02-27 |
| ZA201207670B (en) | 2013-05-29 |
| WO2011131943A3 (en) | 2011-12-29 |
| KR20130076818A (ko) | 2013-07-08 |
| NZ602955A (en) | 2015-02-27 |
| AU2011244783B2 (en) | 2015-11-12 |
| AU2011244783A1 (en) | 2012-11-01 |
| JP2013525337A (ja) | 2013-06-20 |
| RU2012149115A (ru) | 2014-05-27 |
| US20130302415A1 (en) | 2013-11-14 |
| BR112012026843A2 (pt) | 2016-07-12 |
| CA2796494A1 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201200284A (es) | Composición farmacéutica | |
| BR112013007362A2 (pt) | composição farmacêutica | |
| MX336741B (es) | Composiciones farmaceuticas de moduladores de c-met. | |
| CO6980625A2 (es) | Composiciones que generan perácidos | |
| EP2616076A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| BR112013003536A2 (pt) | composição, e utilização de uma composição. | |
| EP2758052A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| ECSP10010622A (es) | Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina | |
| CO7160079A2 (es) | Composiciones líquidas de racecadotrillo | |
| BRPI1005931A8 (pt) | associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica | |
| BR112014001219A2 (pt) | perfume | |
| BR112013028039A2 (pt) | composição de cimento | |
| MX2013006644A (es) | Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina. | |
| BR112013012313A2 (pt) | combinação farmacêutica de paclitaxel e um inibidor de cdk | |
| BR112013027403A2 (pt) | composições que compreendem uma antimetabólito de glicose e selênio | |
| EP2769718A4 (en) | MEDICAL COMPOSITION | |
| AR082215A1 (es) | Composicion farmaceutica agradable al paladar | |
| CU24163B1 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| BR112013011650A2 (pt) | embalagem com rasgamento por pressão | |
| BR112015004813A2 (pt) | composição de sabão, método de desinfecção de uma superfície e utilizações de uma composição | |
| BR112012020940A2 (pt) | artigo fabricado com uma composição poliolefínica | |
| ITTO20110268A1 (it) | Composizione di maquillage. | |
| HRP20130082A2 (hr) | Farmaceutski pripravak za produljeno oslobađanje trimetazidina | |
| DOP2013000258A (es) | Formulaciones de liberación sostenida de paracetamol | |
| BR112013033127A2 (pt) | suplemento alimentar, composição alimentar e forma de dosagem |